Charlson Comorbidity Index (CCI)
Determines the 10-year survival in patients suffering from multiple comorbidities.
In the text below the calculator there are instructions on how the index score is calculated and information about the original study.
The Charlson comorbidity index evaluates the survival/mortality risk for the next 10 years in patients who suffer from several conditions such as congestive heart failure or diabetes.
It is aimed at simplifying decision making for medical specialists, regarding different screenings and procedures that the patient might or might not live to benefit from.
It consists of 17 items, one of which is the patient age and the others are comorbidities that are weighted differently in the score.
Each of the items in the index is awarded a number of points which are then summed:
■ 1 point conditions – Myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, connective tissue disease, ulcer, chronic liver disease, diabetes mellitus.
■ 2 point conditions - Hemiplegia, moderate to severe kidney disease, diabetes mellitus with end organ damage, solid tumor, leukemia, lymphoma.
■ 3 point condition - Moderate to severe liver disease.
■ 6 point conditions - Malignant tumor, metastasis, AIDS.
S is the result from summing the points.
CCI ten year survival = 0.983A where A = e (S x 0.9)
Send Us Your Feedback
Steps on how to print your input & results:
1. Fill in the calculator/tool with your values and/or your answer choices and press Calculate.
2. Then you can click on the Print button to open a PDF in a separate window with the inputs and results. You can further save the PDF or print it.
Please note that once you have closed the PDF you need to click on the Calculate button before you try opening it again, otherwise the input and/or results may not appear in the pdf.
Charlson comorbidity index explained
The CCI is a survival stratification tool that assesses the comorbidity risk associated with several conditions.
It allows medical specialists to make informed decisions in regard to procedures that patients may or not benefit from.
The CCI basically predicts the ten-year survival, therefore informing the medical specialist about how the comorbidities the patient is suffering from impact their life expectancy, thus helping them decide upon the short and long term benefits of the treatment they are about to recommend.
Comorbidities of patients are defined using the International Classification of Diseases (ICD) diagnosis codes.
Comorbidity is defined as the presence of one or more additional conditions existing simultaneously, independently or not (with or without a causal effect) with a disease that is considered primary.
In the CCI the patient’s age is allocated to one of the age groups, each considered to be of a different risk.
The following table introduces the conditions used in the comorbidity index and the number of points they are awarded:
Charlson index item | Points | Other notes |
Myocardial Infarction (MI) | 1 | commonly heart attack, either patient or family history |
Congestive Heart Failure (CHF) | 1 | high output cardiac failure |
Peripheral Vascular Disease (PVD) | 1 | peripheral artery occlusive disease and peripheral obliterative arteriopathy |
Cerebrovascular Disease (CVA) | 1 | impaired mental processes with memory loss |
Dementia | 1 | - |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | pulmonary disease |
Connective Tissue Disease | 1 | group of diseases affecting the bodies connective tissue such as fat, bone or cartilage |
Peptic Ulcer Disease | 1 | ulceration of the stomach and/ or first part of the small intestine lining |
Diabetes Mellitus | 1 or 2 | score of 1 for uncomplicated and 2 for end organ damage |
Chronic Kidney Disease (CKD) | 2 | impaired renal function to different degrees (moderate to severe) |
Hemiplegia | 2 | weakness of one entire half side of the body, consequence or not of stroke |
Leukemia | 2 | malignancy consisting in increased number of immature and/or abnormal leucocytes |
Malignant Lymphoma | 2 | cancerous spread in the lymph system |
Solid tumor | 2 or 6 | 2 in case of presence and 6 in case tumor is metastatic |
Liver disease | 1 or 3 | hepatic function damage caused by alcohol, viral or genetic agents (mild 1 point, moderate to severe 3 points) |
AIDS | 6 | Acquired Immune Deficiency Syndrome caused by the Human Immunodeficiency Virus (HIV) |
CCI scoring
As described in the table above, each of the items in the CCI is awarded a number of points, which are summed according to the answers about the patient. The index score is further calculated through the following method, which is also used in the CCI calculator:
S – result from point addition
CCI ten year survival = 0.983A where A = e (S x 0.9)
As an example, for a CCI score of 6, the ten year survival is 2.25%.
About the study
The index was created by Charlson et al. in 1987 following a study initially on a cohort of 559 medical patients for the 1-year survival and then on a cohort of 685 patients for the 10-year survival method.
It was aimed at usage within longitudinal studies that involved conditions which might alter the risk of mortality.
The CCI was found to perform similarly to a previous system devised by Kaplan and Feinstein.
A subsequent validation study was performed on 226 patients with hypertension or diabetes who underwent elective surgery.
In time there have been built different variations such as the Charlson-Deyo, Charlson-Romano, Charlson-Manitoba and Charlson-D'Hoores comorbidity indices.
Original study
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83.
Validation
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47(11):1245-51.
Specialty: Emergency
Objective: Survival Stratification
Type: Index
No. Of Items: 17
Year Of Study: 1987
Abbreviation: CCI
Article By: Denise Nedea
Published On: April 5, 2017 · 10:10 AM
Last Checked: April 5, 2017
Next Review: April 5, 2023